- Study name RaPsOdy was added at the end of the study title - All secondary endpoints were added - Inclusion and exclusion criteria were edited to better define the selection of the study population - Added development of malignancy while on study as a reason for subject withdrawal - Added instruction that subjects who discontinued early would return for all Part 1 study visits - Clarified that “dropouts” referred to subjects who discontinued early and who were randomized but not treated - Revised instructions for used syringes - Edited language around prior and concomitant medications - Clarified that the same Investigator/clinician should have conducted the PASI for each subject at each visit - Added clarification that injection site reactions should have only been reported as adverse events if they were observed by study personnel - Changed Grade 4 adverse event definition from “severe” to “life-threatening” - Clarified that subjects with an indeterminate QuantiFERON-TB Gold test result could have had the test repeated once, and if negative, could have participated in the study

- Prohibited administration of a live vaccine within 4 weeks prior to screening - Added language to clarify text around study drug accountability and retention as a safety measure, and to maintain consistency with the product insert of etanercept - Updated testing methods for positive HIV results

- Revised enrollment numbers - Clarified that a subject’s last dose is at Week 47 - Added text to clarify requirements for the use of abstinence as a means of birth control - Added requirement that study personnel should visually inspect syringes for particulate matter and/or discoloration prior to dispensing study drug - Clarified TB testing entry criteria and what results permitted a repeat test - Clarified when subjects should have returned for follow-up after last dose of study drug - Added an explanation on how to manage subjects who were enrolled prior to study drug suspension - Prohibited systemic steroids within 4 weeks of randomization - Clarified that subjects who were off study drug during the study drug suspension period could have resumed study drug regardless of how many doses were missed - Expanded the 2 primary endpoints of the study - Added a description of adverse event outcomes - Added language to allow continuation into an open-label extension study in select countries - Redefined the Full Analysis Population and Safety Population

- Added durability of response as an efficacy variable for Part 2 - Added detailed information to the interpretation of QuantiFERON-TB Gold testing and how subjects who had an intermediate or low positive result should be managed - Added language stating that the Sponsor may review A/B unblinded Part 1 analyses to assess if the results can support the project regulatory strategy and may release the assessment publically